文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

LSINCT5:癌症中一种关键的致癌长链非编码RNA。

LSINCT5: a pivotal oncogenic long non-coding RNA in cancers.

作者信息

Sritharan Sharanya K, Arifin Amar Harris, Salvamani Shamala, Koh Rhun Yian, Gunasekaran Baskaran

机构信息

Division of Applied Biomedical Sciences and Biotechnology, School of Health Sciences, IMU University, Kuala Lumpur, Malaysia.

Centre for Postgraduate Studies, IMU University, Kuala Lumpur, Malaysia.

出版信息

Funct Integr Genomics. 2025 Jun 2;25(1):115. doi: 10.1007/s10142-025-01610-4.


DOI:10.1007/s10142-025-01610-4
PMID:40455308
Abstract

Long stress-induced non-coding transcript 5 (LSINCT5) is a long non-coding RNA (lncRNA) that has been demonstrated to exhibit oncogenic properties as its upregulation was found to be commonly associated with malignant clinicopathological features in various cancers. Numerous studies have reported that LSINCT5 overexpression may promote cancer progression by regulating the expression of genes that modulate important aspects of cell activity and by interfering with signalling pathways via precise mechanisms such as microRNA (miRNA) sponging, protein interactions, as well as acting as a downstream target of transcription factors. Eventually, these processes stimulate malignant behaviour such as proliferation, invasion, migration, and epithelial-mesenchymal transition (EMT). Research suggests LSINCT5 could be a useful biomarker and therapeutic target. However, understanding their complex nature and impact on physiological processes is crucial for determining their oncogenic properties and potential use in therapy. This review focuses on LSINCT5's biological functions, expression patterns, oncogenic roles, and molecular mechanisms in cancers. We further highlight the potential of LSINCT5 as a biomarker for early diagnosis and prognosis, as well as a therapeutic target in cancer therapy.

摘要

长应激诱导非编码转录本5(LSINCT5)是一种长链非编码RNA(lncRNA),已被证明具有致癌特性,因为其上调通常与多种癌症的恶性临床病理特征相关。大量研究报告称,LSINCT5的过表达可能通过调节影响细胞活动重要方面的基因表达,以及通过诸如微小RNA(miRNA)海绵作用、蛋白质相互作用等精确机制干扰信号通路,还通过作为转录因子的下游靶点来促进癌症进展。最终,这些过程会刺激增殖、侵袭、迁移和上皮-间质转化(EMT)等恶性行为。研究表明,LSINCT5可能是一种有用的生物标志物和治疗靶点。然而,了解它们的复杂性质及其对生理过程的影响对于确定其致癌特性和在治疗中的潜在用途至关重要。本综述重点关注LSINCT5在癌症中的生物学功能、表达模式、致癌作用和分子机制。我们进一步强调了LSINCT5作为早期诊断和预后生物标志物以及癌症治疗中治疗靶点的潜力。

相似文献

[1]
LSINCT5: a pivotal oncogenic long non-coding RNA in cancers.

Funct Integr Genomics. 2025-6-2

[2]
LSINCT5: A Novel lncRNA in Cancers.

Curr Med Chem. 2023

[3]
The long non-coding RNA LSINCT5 promotes malignancy in non-small cell lung cancer by stabilizing HMGA2.

Cell Cycle. 2018-7-5

[4]
Long Stress Induced Non-Coding Transcripts 5 (LSINCT5) Promotes Hepatocellular Carcinoma Progression Through Interaction with High-Mobility Group AT-hook 2 and MiR-4516.

Med Sci Monit. 2018-11-25

[5]
Long noncoding RNA LSINCT5 is upregulated and promotes the progression of esophageal squamous cell carcinoma.

Eur Rev Med Pharmacol Sci. 2019-6

[6]
Long non-coding RNA LSINCT5 predicts negative prognosis and exhibits oncogenic activity in gastric cancer.

Medicine (Baltimore). 2014-12

[7]
PSMA3-AS1: a promising LncRNA as a diagnostic and prognostic biomarker in human cancers.

Gene. 2025-8-10

[8]
The role of long non-coding RNA BCAR4 in human cancers.

Hum Cell. 2021-9

[9]
LSINCT5 activates Wnt/β-catenin signaling by interacting with NCYM to promote bladder cancer progression.

Biochem Biophys Res Commun. 2018-5-30

[10]
Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p.

Mol Cancer. 2017-7-11

本文引用的文献

[1]
Unraveling the role of LncRNAs in glioblastoma progression: insights into signaling pathways and therapeutic potential.

Metab Brain Dis. 2024-11-26

[2]
Targeting and engineering long non-coding RNAs for cancer therapy.

Nat Rev Genet. 2024-8

[3]
HMGA2 promotes cancer metastasis by regulating epithelial-mesenchymal transition.

Front Oncol. 2024-2-1

[4]
CRNDE: A Pivotal Oncogenic Long Non-Coding RNA in Cancers.

Yale J Biol Med. 2023-12

[5]
H19: An Oncogenic Long Non-coding RNA in Colorectal Cancer.

Yale J Biol Med. 2023-12

[6]
Nucleic acid degradation as barrier to gene delivery: a guide to understand and overcome nuclease activity.

Chem Soc Rev. 2024-1-2

[7]
An Overview of the Immune Modulatory Properties of Long Non-Coding RNAs and Their Potential Use as Therapeutic Targets in Cancer.

Noncoding RNA. 2023-11-11

[8]
The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring.

Cell Rep Med. 2023-10-17

[9]
Role of long non-coding RNAs in pancreatic cancer pathogenesis and treatment resistance- A review.

Pathol Res Pract. 2023-5

[10]
Global burden and trends of lung cancer incidence and mortality.

Chin Med J (Engl). 2023-7-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索